Since 1993, Armstrong has focused exclusively on pharmaceutical products, primarily in the area of inhaled respiratory drugs that are delivered by Metered Dose Inhalers (MDIs).

On October 9, 2003, Amphastar Pharmaceuticals, Inc., a specialty and generic pharmaceutical company, acquired Armstrong.

In line with Amphastar’s strong R&D background, Armstrong’s pipeline will continue to build upon the substantial experience achieved in the development, manufacture and marketing (mainly in the U.S.) of inhaled respiratory drugs, primarily for bronchial asthma and chronic obstructive pulmonary disease, delivered by Metered Dose Inhalers (MDIs).

At the core of Armstrong’s efforts to grow its respiratory business, a continued investment in manufacturing capacity both for Metered Dose Inhalers (MDIs) and nasal sprays, will allow Armstrong to play an important role in all major markets where it operates.

Armstrong currently markets two products in the US: Primatene® Mist (Epinephrine Inhalation Aerosol Bronchodilator) and generic Albuterol CFC Metered Dose Inhaler. These products are generally available in most major food, drug and mass merchandise retailers across the U.S.  (Albuterol requires a prescription.) 

Armstrong is also seeking FDA approval for Albuterol Sulfate MDI containing hydrofluoroalkane (HFA).

Click Here for:

Primatene® Mist is the fastest type of Asthma relief available without a prescription, and is the #1 Over-The-Counter (OTC) medicine sold for the relief of physician-diagnosed Bronchial Asthma.